Skip to content

Author

I. Kotsantis

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING).

INTRODUCTION The aim of the present clinical trial was to evaluate the efficacy and toxicity of ramucirumab in combination with nab-paclitaxel and gemcitabine as first-line treatment in locally advanced or metastatic pancreatic adenocarcinoma. METHODS This was a prospective, single-arm, phase Ib-II trial. In phase Ib...

G. Papaxoinis, J. Sgouros, N. Korfiatis et al. · 0 citations
Case report Open access Jul 2026

Immune-mediated liver injury caused by checkpoint inhibitors: A case series and review of the literature.

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 agents, exhibit notable efficacy across various types of cancer. Nevertheless, they can trigger immune-related adverse events, among which immune-mediated liver injury (ILICI) occurs in 5-10% of patients. Corticosteroids are currently recommended...

M. Kyrkasiadou, A. Kyriazoglou, I. Kotsantis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.